KHK6640 Phase1 study (A repeated dose study in patients with Alzheimer's disease)

KHK6640 Phase1 study (A Phase1 Randomized, Placebo-Controlled, Double-Blind, Repeated Dose Study of KHK6640 in Japanese Patients with Alzheimer's Disease)

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223486

Enrollment

Registered

2017-03-22

Start date

2017-03-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease (AD)

Interventions

investigational material(s) Generic name etc : KHK6640 INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients with mild to moderate AD - Body weight >= 40 kg and = 17 and =< 26

Exclusion criteria

Exclusion criteria: - Previous active treatment with an AD immunotherapy in an investigational study - Use of another investigational drug within 16 weeks prior to the enrollment - Subjects who meet National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria for vascular dementia - Subjects with a history of presence of clinically significant seizures, brain trauma, transient ischemic attack, and/or cerebrovascular disease - Subjects who have evidence of infection, tumor, or other clinically significant lesions that could indicate a dementia diagnosis other than AD - Subjects with a presence of a neurological condition that could be contributing to cognitive impairment above and beyond that caused by the subject's AD

Design outcomes

Primary

Measure	Time frame
Safety Safety (adverse events)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026